Corticosteroid Therapy for Severe Community-Acquired Pneumonia

Summary

The purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (PSI 4-5).

The hypothesis of the study is that methylprednisolone can decrease the mortality of severe CAP without any significant side effects,with reduction of the time to clinical stability and failure rate of treatment.

Conditions

• Community Acquired Pneumonia

Interventions

DRUG

methylprednisolone

DRUG

Normal saline

Sponsors & Collaborators

• The Second Hospital of Hebei Medical University

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Cangzhou Central Hospital

  collaborator OTHER

• Cangzhou People's Hospital

  collaborator OTHER

• Affiliated Hospital of Hebei University

  collaborator OTHER

• Nantong University

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Northern Jiangsu People's Hospital

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• Taishan Medical University Affiliated Hospital

  collaborator OTHER

• Tianjin Third Central Hospital

  collaborator OTHER

• Jinhua Central Hospital

  collaborator OTHER

• Navy General Hospital, Beijing

  collaborator OTHER

• Peking Union Medical College Hospital

  lead OTHER

Principal Investigators

• Xuezhong Yu, MD · Peking Union Medical College Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-05-31

Primary Completion

2017-05-31

Completion

2017-05-31

Countries

• China

Study Locations